Medicure Inc (MPH)

Currency in CAD
1.1500
0.0000(0.00%)
Closed·
MPH is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.15001.1500
52 wk Range
0.63001.4300
Key Statistics
Bid/Ask
1.15 / 1.30
Prev. Close
1.15
Open
1.15
Day's Range
1.15-1.15
52 wk Range
0.63-1.43
Volume
-
Average Volume (3m)
5.04K
1-Year Change
59.7222%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MPH Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low revenue valuation multiple

Medicure Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Medicure Inc Company Profile

Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing MC-1 for the treatment of PNPO deficiency; and TARDOXAL for neurological indications, such as Tardive Dyskinesia. It offers products through retail and mail order pharmacies. The company was founded in 1997 and is headquartered in Winnipeg, Canada.

Medicure Inc Earnings Call Summary for Q3/2025

  • Medicure Q3 2025 revenue rose to CAD 8.2M (up from CAD 5.2M in Q3 2024), though the company reported a net loss of CAD 1.4M (CAD 0.13 per share).
  • Stock surged 34.91% to CAD 1.43 (52-week high) despite financial challenges, reflecting investor confidence in revenue growth trajectory.
  • Zypitamag and Marley Drug delivered double-digit sales growth, while cash reserves declined to CAD 4.1M from CAD 7.2M in December 2024.
  • Company remains debt-free with strategic focus on expanding pharmacy business, increasing Zypitamag sales, and advancing MC-1 for FDA approval.
  • Key challenges include increased competition for Aggrastat from generic Tirofiban, low market awareness for Zypitamag, and declining cash reserves.
Last Updated: 2025-11-20, 09:32 a/m
Read Full Transcript

Compare MPH to Peers and Sector

Metrics to compare
MPH
Peers
Sector
Relationship
P/E Ratio
−3.5x−3.9x−0.5x
PEG Ratio
0.05−0.020.00
Price/Book
0.7x1.6x2.6x
Price / LTM Sales
0.5x2.3x3.3x
Upside (Analyst Target)
-117.4%45.7%
Fair Value Upside
Unlock2.8%6.5%Unlock
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
Nov 19, 2025
EPS / Forecast
-0.13 / --
Revenue / Forecast
8.16M / --
EPS Revisions
Last 90 days

MPH Income Statement

FAQ

What Is the Medicure (MPH) Stock Price Today?

The Medicure stock price today is 1.1500

What Stock Exchange Does Medicure Trade On?

Medicure is listed and trades on the TSX Venture Exchange.

What Is the Stock Symbol for Medicure?

The stock symbol for Medicure is "MPH."

What Is the Medicure Market Cap?

As of today, Medicure market cap is 12.00M.

What Is Medicure's Earnings Per Share (TTM)?

The Medicure EPS (TTM) is -0.33.

When Is the Next Medicure Earnings Date?

Medicure will release its next earnings report on Apr 22, 2026.

From a Technical Analysis Perspective, Is MPH a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Medicure Stock Split?

Medicure has split 1 times.

How Many Employees Does Medicure Have?

Medicure has 38 employees.

What is the current trading status of Medicure (MPH)?

As of Feb 07, 2026, Medicure (MPH) is trading at a price of 1.1500, with a previous close of 1.1500. The stock has fluctuated within a day range of 1.1500 to 1.1500, while its 52-week range spans from 0.6300 to 1.4300.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.